InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
4,967.23
(
-0.88%
)
US TECH 100
16,556.80
(
-2.24%
)
Dow Jones
37,986.40
(
0.56%
)
Brent Oil
86.63
(
0.00%
)
Bitcoin
63,806.73
(
-0.02%
)
Post# of 83
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

busker

Send PM Follow Ignore
Followers 0
Posts 29
Boards Moderated 0
Alias Born 09/27/2006

busker

Re: None

Wednesday, 09/19/2007 4:26:15 PM

Wednesday, September 19, 2007 4:26:15 PM

Post# of 83
Analyst Ben McCaw from eGCapital has released a new and very detailed research report dated 19 September 2007.

In the well researched and well written report McCaw make extensive comments and observations about the NSCLC trial.
The data from this trial is due to for released to the market before the end of this month.

Included in the 8-page research report is eGC’s recommendation and valuation for Progen.

BUY rating with valuation of AUD16.45 (USD14.05)

The following comment is included in relation to the share price valuation:

"Before discussing our view on the upcoming [NSCLC] data, we remind investors that our standing valuation of PGL focuses exclusively on the liver cancer project"

busker.the.dog@lycos.com

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up